Sorrento Therapeutics faced a financial and legal crisis in February 2023, and needed to file for bankruptcy. The pharmaceutical developer’s chief executive and chief financial officers met with ...

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is ...

Kintara Therapeutics, Inc., a clinical stage drug ... non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of ...

A digital therapeutic (DTx) is defined as “health software intended to treat or alleviate a disease, disorder, condition, or injury by generating and delivering a medical intervention that has a ...

BOSTON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today ...

This can also be displayed by a low stock price compared to its intrinsic value ... company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as ...

Viking Therapeutics stock has already tripled in 2024, but Wall Street analysts think it has more room to run. Viking Therapeutics' lead candidate is an experimental weight management treatment ...

With every major advancement in the field of aging biology, humankind is one step closer to turning back the clock and restoring our youth. In ...

View the PTCT option chain and compare options of PTC Therapeutics Inc stock. Analyze the various options available, including call options (the right to buy) and put options (the right to sell ...

View the VKTX option chain and compare options of Viking Therapeutics Inc stock. Analyze the various options available, including call options (the right to buy) and put options (the right to sell ...

Although the role of innate immune sensing pathways is well-studied in the pathogenesis of malignancies, whether they ...

Bicara Therapeutics’ shares are expected to begin ... anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation, as well as the immunosuppressive ...